Serum Orotidine: A Novel Biomarker of Increased CVD Risk in Type 2 Diabetes Discovered Through Metabolomics Studies.
Hetal S ShahLorena Ortega MorenoMario Luca MorieriYaling TangChristine MendoncaJenny Marie JobeJonathan B ThackerJoanna MitriStefano MontiMonika A NiewczasSubramaniam PennathurAlessandro DoriaPublished in: Diabetes care (2022)
Through a robust metabolomics approach, with independent validation, we have discovered serum orotidine as a novel biomarker of increased odds of CVD in T2D, independent of renal function. Additionally, orotidine may be a biological mediator of the increased CVD risk associated with poor kidney function and may help improve CVD risk prediction in T2D.